We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Adaptive Biotechnologies Corp (ADPT) USD0.0001

Sell:$14.95 Buy:$14.99 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Contact details

United States
+1 (206) 6590067

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.22 billion
Shares in issue:
141.13 million
Life Sciences Tools & Services
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Chad Robins
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Julie Rubinstein
  • Harlan Robins
    Co-Founder, Chief Scientific Officer
  • Chad Cohen
    Chief Financial Officer
  • Mark Adams
    Chief Operating Officer
  • Francis Lo
    Chief People Officer
  • Stacy Taylor
    Senior Vice President, General Counsel
  • Susan Bobulsky
    Senior Vice President - Diagnostics, clonoSEQ
  • Jyoti Palaniappan
    Senior Vice President - Diagnostics, T-Detect (formerly immunoSEQ Dx)
  • Henning Thorsen
    Senior Vice President - Commercial Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.